Lexeo Therapeutics, Inc. 8-K

What Happened

• Lexeo Therapeutics, Inc. filed a Current Report on Form 8-K on June 15, 2026 disclosing a corporate presentation that will be used in connection with an investor webcast and furnishing a related press release. The disclosure was made under Item 7.01 (Regulation FD disclosure) and Item 8.01 (Other events).
• The filing includes exhibits with the June 15, 2026 press release and two versions of the corporate presentation; the report is signed by CEO R. Nolan Townsend.

Key Details

• Filing date: June 15, 2026 (Form 8-K).
• Items reported: 7.01 (Regulation FD Disclosure) and 8.01 (Other Events).
• Exhibits furnished: Press release (Exhibit 99.1) and corporate presentation(s) dated June 15, 2026 (Exhibits 99.2 and 99.3); Inline XBRL cover page filed (Exhibit 104).
• Report signed by R. Nolan Townsend, Chief Executive Officer.

Why It Matters

• The company publicly furnished its investor presentation and press release, satisfying Regulation FD requirements to disclose information broadly rather than selectively. That helps ensure all investors have equal access to the same corporate update and materials.
• For retail investors, this means new company messaging and any material updates presented in the deck or press release are now public and can be reviewed directly; any information relevant to investment decisions should be assessed by reading the furnished presentation and press release.